Article
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.
Clinical lung cancer - 1 Jan 2017
Garon Edward B, Reck Martin, Paz-Ares Luis, Ponce Santiago, Jaime Jesus Corral, Juan Oscar, Nadal Ernest, Lee Pablo, Dalal Rita, Liu Jingyi, He Shuang, Treat Joseph, Nakagawa Kazuhiko
Abstract excerpt
INTRODUCTION: We present the treatment rationale and study design for the RELAY study (NCT02411448 ). This phase Ib/III study will assess safety, tolerability, and efficacy of the combination of ramucirumab with erlotinib in previously untreated stage IV non-small-cell lung cancer patients with an activating epidermal growth factor receptor (EGFR) mutation. PATIENTS AND METHODS: The study is being conducted in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.